Maarten de Groot, MolGen CEO, and Colin Denver, SpeeDx CEO
Maarten de Groot, MolGen CEO, and Colin Denver, SpeeDx CEO

Image source: MolGen/SpeeDx

News • Sample-to-answer workflow

Partnership for Covid-19 test solution

SpeeDx Pty, Ltd. and MolGen announced the signing of an agreement to collaborate on supply and distribution of clinical diagnostics products and instrumentation across Europe and Asia Pacific.

The partnership links specimen handling, nucleic acid extraction, assay set-up, amplification, and results reporting in a seamless integration of the companies technologies. “This partnership capitalises on the existing infrastructure of our two companies and the strength of our synergies,” said Colin Denver, SpeeDx CEO. “Our commitment to providing products and services that answer unmet clinical needs also extends to the pathology laboratories that are running our tests – in partnership with MolGen, we can address much of their workflow concerns and offer a more complete testing solution.”

Throughout the past year of Covid-19, in response to the increased demand for molecular testing workflow solutions, MolGen has developed a comprehensive offering including the PurePrep nucleic acid extraction portfolio, liquid handling instrumentation and other purpose-built automation to facilitate high-volume testing of SARS-CoV-2. SpeeDx complete the partnership with an initial offer of their CE-IVD SARS-CoV-2 test based on their proprietary PlexPCR technology, allowing pathology laboratories a single point of contact to fulfil their testing needs.

“For MolGen, the collaboration with SpeeDx is a perfect example of combining the best of both worlds. Our DNA and RNA extraction solutions and automated workflow perfectly pair with SpeeDx diagnostic assay technology” said Maarten de Groot, MolGen CEO. “During the Covid pandemic adding the CE-IVD SARS-CoV-2 assay to our diagnostics portfolio is great opportunity to start our collaboration. And this is only the beginning of jointly building an innovative product portfolio”.


Source: MolGen/SpeeDx

06.07.2021

Read all latest stories

Related articles

Photo

Sponsored • Pathogen detection

MolGen introduces high quality DNA/RNA extraction kits for efficient high throughput testing

SARS-CoV-2 has heavily impacted global society with high pressure on public health and economics. MolGen is proud to assist in relieving some of the pressure and support the testing framework.

Photo

News • Early detection of coronavirus presence

Covid-19 wastewater testing: new quantification kit launched

Life science research and clinical diagnostics company Bio-Rad Laboratories announced the launch of its PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit, a tool to detect the virus that…

Photo

Sponsored • Disease management

Multiplex Testing: A Solution to Manage Surge in Respiratory Illnesses as Concerns over “Multi-demic” Rise

Eunsin Bae, M.D. specializes in laboratory medicine and leads the Institute of Clinical Research at Seegene Inc. Her research focuses on microbiology, molecular biology, and hematology. Dr. Bae is…

Related products

CliniSys – Anatomical Pathology Laboratory

Information Technology

CliniSys – Anatomical Pathology Laboratory

CliniSys Deutschland GmbH
Mesalvo – LabCentre

LIS, Middleware, POCT

Mesalvo – LabCentre

Mesalvo Mannheim GmbH (ehemals i-SOLUTIONS Health GmbH)
Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Subscribe to Newsletter